REFERENCE:

- [1] Watts R, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. *Annals of the Rheumatic Diseases* 2007.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.4771

FRI0486

POTENTIAL PREDICTORS OF VISCERAL INVOLVEMENT IN ADULT IGA VASCULITIS

A. Hocevar¹, Ž. Rotar¹, V. Jurčić², M. Tomšič¹. ¹Dpt. of Rheumatology, University Medical Center Ljubljana; ²Institute of Pathology, Faculty of Medicine, University of Ljubljana, LJUBLJANA, Slovenia

Background: Predictors of severity of visceral involvement in acute adult IgA vasculitis (IgAV) are poorly recognised.

Objectives: The aim of our study was to evaluate the role of smoking and extension of skin lesions on the visceral manifestations of acute adult IgA vasculitis.

Methods: We analysed medical records of adult, histologically proven IgAV cases, diagnosed at our secondary/tertiary rheumatology centre between 1 January 2010 and 31 December 2017. Purpura was defined as generalised when skin lesions extended above the waistline. Gastrointestinal (GI) disease was considered severe in case of bloody diarrhoea, ileus or bowel perforation. Renal disease was defined as severe when nephritic syndrome with acute renal failure or nephrotic syndrome developed.

Results: During the study period we identified 230 incident IgAV cases (57.8% males, median (IQR) age 64.8 (45.6–77.3) years). Ninety-eight (42.6%) patients were smokers (56 past and 42 current). Skin, joint, GI, renal and involvement were present in 230 (generalised purpura in 114 (49.6%), necrotizing in 108 (47.0%), 93 (40.4%), 70 (30.4%; severe in 17) and 102 (44.3%; severe in 27) patients, respectively. Smoking was associated with renal disease (RR 1.3 (95% CI 1.0–1.8)) and its severity (RR 3.2 (95% CI 1.5–7.0)), but not with GI involvement or its severity. Generalised purpura was associated with GI involvement (RR 2.9 (95% CI 1.8–4.7) and its severity (RR 3.3 (95% CI 1.1–9.8)), as well as with renal involvement (RR 1.4 (95% CI 1.0–1.9)). Data of combined influence of smoking and purpura extension on visceral involvement are presented in table 1. The risk of severe renal involvement in IgAV was the highest in ever-smoker with generalised purpura (RR 8.1 (95% CI 1.9–34.7) in comparison to IgAV non-smoker with localised purpura).

Table 1 The influence of smoking and purpura extension on visceral involvement in IgAV

Visceral involvement	Nonsmokers with localized purpura	Ever-smokers with localized purpura	Nonsmokers with generalized purpura	Ever-smokers with generalized purpura
Number of cases	69	47	63	51
GI (%)	13.0	19.1	47.6	43.1
Severe GI (%)	2.9	4.3	11.1	11.8
Renal (%)	30.4	46.8	47.6	56.9
Severe renal (%)	2.9	14.9	9.5	23.5

Legend: GI gastrointestinal; severe GI involvement: bloody diarrhea or ileus or bowel perforation; severe renal involvement: nephritic syndrome with acute renal failure or nephrotic syndrome;

Conclusions: Smoking and generalised purpura were associated with visceral involvement in adult IgAV.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.2747

FRI0487

SERUM INTERLEUKIN-6 LEVELS IN ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS

A. Berti^{1,2,3}, R. Warner⁴, K. Johnson⁴, D. Cornec¹, D. Schroeder¹, B. Kabat¹, C. A. Langford⁵, G.S. Hoffman⁶, C.G. Kallenberg⁶, P. Seo⁷, R. Spiera⁸, W. E. St. Clair⁹, F. Fervenza¹⁰, J. Stone¹⁰, P. Monach¹¹, U. Specks¹, P.A. Merkel¹², on behalf of the RAVE-ITN Research Group. ¹Mayo Clinic, Rochester, USA; ²San Raffaele Scientific Institute, Milan; ³Santa Chiara Hospital, Trento, Italy; ⁴University of Michigan Medical School, Ann Arbor; ⁵Cleveland Clinic, Cleveland, USA; ⁶University Medical Center Groningen, Groningen, Netherlands; ⁷Johns Hopkins University, Baltimore; ⁸Hospital for Special Surgery, New York; ⁹Duke University, Durham; ¹⁰Massachusetts General Hospital; ¹¹Boston University, Boston; ¹²University of Pennsylvania, Philadelphia, USA

Background: The deregulated overproduction of interleukin (IL)–6 has been implicated in several inflammatory and antibody-mediated autoimmune diseases.

Objectives: To investigate serum IL-6 levels (sIL-6) during active disease, remission, and relapse in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), and to explore the association of changes in sIL-6 with repopulation of blood B cells and disease relapse.

Methods: sIL-6 levels (explanatory variable) were measured longitudinally over 18 months in 78 patients with AAV enrolled in a prospective, double-blinded, randomised, control trial comparing treatment with rituximab (RTX) (n=45) or cyclophosphamide (CYC)/azathioprine (AZA) (n=33). Outcome variables included baseline clinical features, ANCA type and titers, disease activity (status of active disease versus complete remission (CR)), time to B cell repopulation, relapse and severe relapse.

Results: Baseline sIL6 levels were detectable (>0.49 pg/ml) in 81% of patients. At baseline, sIL-6 positively correlated with proteinase (PR3)-ANCA levels ($r_s=0.36$, $p<0.01$), but not with myeloperoxidase (MPO)-ANCA levels ($r_s=-0.17$, $p=0.47$). Higher baseline sIL-6 levels were associated with the presence of fever, pulmonary nodules/cavities, PR3-ANCA, and absence of renal involvement ($p<0.05$ for all comparisons).

The median sIL-6 level was higher at baseline and promptly declined with induction therapy at following time-points (baseline, median [25%–75% IQR], 2.66 [0.76–20.98]; month 6th, 0.49 [0.49–1.16]; $p<0.01$) in a similar fashion in both treatment arms.

An increase in sIL-6 during clinical remission was a predictor for subsequent severe relapse in RTX-treated patients (Hazard Ratio (HR) 7.24, $p=0.01$), but not in CYC/AZA-treated patients (HR 0.62, $p=0.50$).

In RTX-treated B cell depleted patients (CD19 +B cell/microliter<10), the rise of sIL-6 levels did not precede B cell reappearance, regardless of whether a cut-off of ≥ 10 CD19+B cell/microliter (HR=0.97; $p=0.97$) or of ≥ 69 CD19+B cell/microliter (HR=1.50; $p=0.41$) was considered. Eighty percent of the patients who subsequently had a severe relapse in the RTX arm had B cell redetection before or at the time of the IL-6 increase, with a mean time between the redetection of B cells and sIL-6 increase of 55 days (25%–75% IQR: 0–184.25; range 0–210 days).

Conclusions: At baseline, sIL-6 correlates with PR3-ANCA titers and associates with the presence of fever and pulmonary nodules/cavities. A rise in sIL-6 levels after complete remission is associated with subsequent severe relapse only in RTX-treated patients. The observed discrepancies between treatments deserve confirmation and further study.

REFERENCES:

- [1] Nishimoto N, et al. Interleukin 6: from bench to bedside. *Nat Clin Pract Rheumatol*. 2006;2(11):619–26.
[2] Stone JH, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. *The New England journal of medicine* 2010;363(3):221–32.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.7362

FRI0488

INSUFFICIENT IMMUNOSUPPRESSIVE USE IS THE LEADING CAUSE OF VASCULAR RELAPSES IN BEHCET'S DISEASE

A. Aksoy¹, F. Alibaz Öner², T. Ergun³, R.H. Direskeneli². ¹Department of Internal Medicine, Division of Rheumatology, Marmara University, School of Medicine; ²Department of Internal Medicine, Division of Rheumatology; ³Department of Dermatology, Marmara University, School of Medicine, Istanbul, Turkey

Background: Vascular involvement is observed in up to 40% in Behcet Disease (BD) patients, as an important cause of mortality and morbidity, especially for males (Kural-Syahi E et al,1984).

Objectives: Purpose of this study is to describe clinical-demographic properties, treatments and prognosis of vascular BD patients in a tertiary rheumatology clinic.

Methods: BD patients fulfilling ISG 1990 criteria are recruited from the multi-disciplinary Behcet's Clinic in Marmara University, Istanbul for this retrospective study. All data is collected from patient files (ISG for BD, 1990).

Results: Mean age of BD patients (M/F:102/22) was 29.3±7.3 years at diagnosis and 32.4±9.5 years old during first vascular event. Median follow up was 47¹⁷⁻⁷¹ months. Mean age of female patients was significantly older during first vascular event (table 1). 73.2% of vascular involvement was venous, mostly deep vein thrombosis (table 2). 32% (n=40) of patients presented first with a vascular event and diagnosed as BD. Twenty (16%) patients were diagnosed with a median of 12¹⁻¹²⁰ months after the first vascular event. 15 (6.5%) patients were using immunosuppressive (IS- mainly azathioprine) drugs either for resistant mucocutaneous symptoms or major other organ involvement during the first vascular event.

Vascular relaps rate was 40.7% and it was similar between sexes (F: 33.3% vs M: 42.2%, $p=0.6$). After the first vascular event, 96 (85.7%) patients had been treated with ISs and 58.9% used anticoagulants. Median IS and anticoagulant usage duration was 25.5 (5–48) and 2 (0–12) months respectively. Relaps rate was higher in patients who had stopped ISs (87.5% vs 32.3%). IS treatment duration